Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
By: salvarai
09 Nov 2004, 11:34 PM EST
Msg. 2840 of 2842
Jump to msg. #
Yes, Good news for HTDS!! Notice guys that the conference was held in Korea and therefore, Artec HAS INDEED the patent rights for Korea, according to the agreement between Shinn and HTDS. Oh well, if Tubercin is as good as these reports say it is, well I don't mind giving up Korea, if we are going to get the Entire World!
This news is very positive as it supports Tubercin's potency in healing diseases. And Frankly, it had been a while since we heard about anything scientific and applied to humans from the discover of Tubercin.
This is Great for HTDS.
November 09, 2004 04:00 PM US Eastern Timezone
Breast Cancer Treatment Introduced at Conference by ArTec
RENO, Nev.--(BUSINESS WIRE)--Nov. 9, 2004--ArTec, Inc., (Pink Sheets:ATKJ) introduced its revolutionary cancer treatment Immunostimulant Tubercin at the 2004 spring meeting of Korean Breast Cancer Society. Dr. Tai Ho Chung (ArTec) made the presentation together with a research team from Kyungpook National University Hospital Daegu, South Korea. The team presented research data demonstrating that Tubercin when combined with conventional cancer treatment such as chemotherapy and other drug therapies promulgated by leading pharmaceutical companies, increases "the efficacy of these treatments by several times in the treatment of breast cancer." Tubercin also proved effective in mitigating certain well-documented side effects of established treatment methods such as leucocytopenia, a deficiency of white blood cells, and peripheral neuritis, an inflammation of the nerves in the arms and legs. Dr. Chung's presentation stated, "We have significant clinical experience that Tubercin can improve leucocytopenia induced by chemo-radio therapy...and other cancer treatments."
ArTec notes that the Korean scientific community considers Tubercin as an alternative or ancillary method to conventional treatments, given the prevalence of breast cancer in Korea. Data collected in a study involving 38 medical schools in South Korea demonstrated a high increase in the number of breast cancer patients and incidence rates. A recent book recently published in Japan, entitled "Immunological Revolution," states, "that when patients with terminal cancer opted for immunotherapy versus chemo-radio therapy, they had a longer life span," a conclusion that supports ArTec's thesis.
Dr. Chung's research team concluded in its presentation to the Breast Cancer Society that Tubercin was not only effective in mitigating commonly occurring side-effects of widely used treatment modalities but, also showed great promise as a preventative treatment by performing a function known as "immunosurveillance" that essentially keeps cancer-fighting T-cells healthy.
Forward-looking statements in this press release, the company cautions the investors, involve risks and uncertainties pursuant to the "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995. In addition, the company cautions investors that it undertakes no obligations or responsibilities to publicly update these forward-looking statements to reflect Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events.
Thanks for updates 2nd Mil
RB Report:
By: salvarai
05 Nov 2004, 03:24 PM EST
Msg. 2812 of 2812
Jump to msg. #
GREAT NEWS! This is the first court indication that Shinn's lawsuit has NO VALUE WHATSOEVER. Once we hear from the injuction's ruling, this whole lawsuit pending on HTDS will be a thing of the past.
This means that once we start receiving results from clinical testings, which are imminent, HTDS is goign to start its ascending ride.
Good days for HTDS right ahead.
Mr. jbenson, and how do we know this is insider trading??
Why do you think HTDS Website states where the testing of Tubercin is being complete?
"The Denver Veteran’s Affairs Medical Center and the University of Colorado Health Sciences Center’s confidence in uses of Tubercin® are self-evident; otherwise they would not have wasted their valuable time and resources."
BUT there is no mention of The Denver Veteran’s Affairs Medical Center and the University of Colorado Health Sciences Center testing on ArTec Inc. Website or press releases.
http://www.artec-inc.net
ATKJ (HTDS Want-To-Be) down 56% today.
Welcome to penny stocks Buffalobill91.
You guys are making this board read like Raging Bull.
Please don't use this board to socialize, like Raging Bull, keep it to the point about SuperWipes Inc.
I don't want investors having their time wasted.
Thankyou
Moderator: abracky
NEW BOARD, SPWP
CLEARWATER, Fla., Oct 18, 2004 (BUSINESS WIRE) -- Superwipes, Inc. (PINK SHEETS:SPWP) is pleased to announce they are in final negations to hire Rene Quenneville as Chief Operating Officer.
Rene possesses over 25 years of experience with Bell Canada and was responsible for building a new enterprise in Brazil, raising the quality of service by implementing ISO norms as well as managing over 1,000 employees. Rene is the brother of Superwipes, Inc. President, Mario Quenneville.
Mario Quenneville, President of Superwipes, Inc., states, "Rene's experience in operations management as well as implementing ISO norms would be invaluable to our company. As we continue to place Superwipes products on the shelves of chain stores through out North America and overseas, we will need some one of his caliber to manage our operational efficiency and growth."
Hard to Treat Diseases Incorporated Receives Judge's Order and Awaits Preliminary Injunction
Tuesday October 12, 10:05 am ET
DELRAY BEACH, Fla., Oct. 12, 2004 (PRIMEZONE) -- Hard to Treat Diseases Incorporated (HTTD) (Other OTC:HTDS.PK - News) received yesterday the Judge's order regarding our Motion For An Emergency Preliminary Injunction against Shinn and his affiliates.
ADVERTISEMENT
The Federal Judge has referred HTTD's Motion For Preliminary Injunction to a United States Magistrate Judge for a report and recommendation on whether a preliminary injunction should issue. The Federal Judge respectfully requested the Magistrate Judge to issue his report at his earliest opportunity and the motion need not be processed as an ``emergency'' matter.
The Federal Judge has denied our request for Emergency Relief since the court finds there to be no emergency in the matter.
``We are confident that the United States court system will protect the rights of HTTD's shareholders,'' stated Colm J. King, President and CEO of Hard to Treat Diseases.
The Courts ruling will be released by HTTD through a press release as soon as it is issued by the Court.
Contact:
Colm J. King
President and CEO
Hard to Treat Diseases, Incorporated
(561) 272-6900
www.htdsotc.com
--------------------------------------------------------------------------------
HERE WE GO WHAT's UP.
October 11, 2004 05:00 AM US Eastern Timezone
ArTec Inc., of Reno, Nevada, Announces Its Readiness to Review PRECLINICAL APPLICATION with US FDA - Tubercin-Anti-Cancer Immunostimulant.
RENO, Nev.--(BUSINESS WIRE)--Oct. 11, 2004--ArTec, Inc., www.artec-inc.net (Pink Sheets:ATKJ) The Pharmaceutical Company's Board of Directors has given a directive to management to prepare for PRECLINICAL US FDA APPLICATION. Specifically, a committee was designated the responsibility to prepare for reviewing PRIVATE MEDICAL REGULATORY CONSULTANTS to lead ArTec, Inc.'s efforts. In the PRECLINICAL phase: in vitro and in vivo, non-human studies are considered. In the same vein, ArTec, Inc., will prepare to review possible PRECLINICAL COLLABORATORS. At the PRECLINICAL stage, determination will be made about the basis for applying under the investigational new drug application (IND) to the FDA.
The stages for PHASE 1, PHASE 2 and PHASE 3 consist of human studies. At the beginning, ArTec, Inc. plans to include resources involving CLINICAL COLLABERATORS, ALLIANCES and possible GRANTS-SPECIAL RESEARCH PROJECTS to assist Tubercin in completing the FDA approval process. No doubt the FAST TRACK status will also be considered in light of the origin of Tubercin at a highly accredited University facility with clinical treatments and evaluations occurring on site.
Tubercin is "carbohydrate complex, which is a mixture of low molecular-weight polysaccharides of an arabinomannan structure extract from Mycobacterium tuberculosis, is highly effective in treating various cancer patients without incurring any adverse side effects." For further information, the US Patent and Trademark Office's Official web site is retrievable at our web site: www.artec-inc.net.
Forward-looking statements in this press release, the company cautions the investors, involve risks and uncertainties pursuant to the "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995. In addition, the company cautions investors that it undertakes no obligations or responsibilities to publicly update these forward-looking statements to reflect Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events.
Contacts
ArTec, Inc., Reno
Gerry Knight, 1-800-388-8875
Email: gknight@artec-inc.net
Website: WWW.artec-inc.net
Thanks Mat
NEW BOARD NEW SYMBOL IS HERE. Superwipes, Inc. SPWP
Could you please remove Superwipes, Inc. (SPSW), this is the wrong symbol. I have opened a new board with the right symbol.
October 09, 2004 05:15 PM US Eastern Timezone
Superwipes, Inc. Symbol Change to SPWP
CLEARWATER, Fla.--(BUSINESS WIRE)--Oct. 9, 2004--Superwipes, Inc. (Pinksheets:SMNC) has received notification from the National Association of Securities Dealers, Inc. (NASD) that effective October 12, 2004, the new symbol for Superwipes, Inc. will be SPWP.
"The Superwipes name and symbol reflect the true identity of the company, the focus of our product line, and the foundation of the future success of the company," said Mario Quenneville, President and CEO of Superwipes, Inc. "This is the next step in our long term plan to steadily build the Company, eventually leading to increased trading accessibility and value for our shareholders."
The name and symbol change to Superwipes, Inc. (Pinksheets:SPWP) does not affect the validity of currently outstanding stock certificates, nor will shareholders be required to surrender or exchange stock certificates at this time.
National Association of Securities Dealers, Inc. (NASD (R))
The largest self-regulatory organization for the securities industry in the United States. NASD is responsible for the operation and regulation of Nasdaq and the over-the-counter securities markets; it is the parent company of NASD Regulation, Inc., and The Nasdaq Stock Market, Inc.
Superwipes, Inc. products can be found in leading food, drug, convenience and beauty supply stores across North America and Europe such as ULTA, Sephora, and Dillards, etc. Superwipes are formulated with organic materials that are safe for the environment and perform with an efficacy equal to or exceeding the toxic chemicals they replace.
Superwipes, Inc. conceives, designs and formulates unique cosmetic and all-purpose products from organic materials with a variety of applications including fingernail polish remover, make up remover, sneaker cleaner wipes, instant shoe shine wipes, acne treatment wipes, eye glass, cleaner and defogger, car interior leather cleaning pads, vitamin E applicators, etc. Superwipes' products are sold in leading food, drug, convenience and beauty supply stores throughout North America and Europe. More Superwipes' products are in various stages of development, and should be released throughout 2004. Please visit www.superwipes.com
This release contains forward-looking information within the meaning of The Private Securities Litigation Act of 1995. Forward-looking statements may be identified through the use of words such as "expects," "will," "anticipates," "estimates," "believes," or statements indicating certain actions "may," "could," "should" or "might" occur. Such forward-looking statements involve certain risks and uncertainties. The actual results may differ materially from such forward-looking statements. The company does not undertake to publicly update or revise its forward-looking statements even if experience or future changes make it clear that any projected results (expressed or implied) will not be realized.
Contacts
Superwipes, Inc. / Taylor Capital Inc.
Stephen Taylor, 973-351-3868
stephtayl9@aol.com
http://www.superwipes.com
New symbol already on E-TRADE ***SPWP*** .022
Do we need a new board?
New Symbol for SuperWipes.
13:34 10/11/2004
SMNC Summit National Consolidation Group Inc Common Stock
SPWP Superwipes, Inc. Common Stock
Hopfully we will know in a week:
By: salvarai
07 Oct 2004, 06:50 PM EDT
Msg. 2708 of 2708
Jump to msg. #
I strongly suspect that any/all activity on Arteck is strictly insider movement. The court should rule on the injunction fairly soon, within a week IMO. And the Sec is also on the case and will react immediately to the ruling. When the court ruling is out, check Artek's stock dive...and HTDS stabilize. In a month from now, we should hear about tests results...In the meantime, this is a buying opportunity. I have added and accumulated.
GLTA
Read "The Motion For Emergency Injunction" at htdsotc.com
and you will learn who the real crooks are and who will own rights to Tubercin. Also maybe The IRS should have a look at Shinn. IMO
ATKJ (HTDS want-to-be) down .15 on low volume
The 800 # in not a good phone number for Artech Inc. Try it.
--------------------------------------------------------------------------------
Contact:
ArTec, Inc.
Gerry Knight, 800-388-8875
gknight@artec-inc.net
www.artec-inc.net
What up with this?????????
Press Release Source: ArTec, Inc.
ArTec, Inc., Of Reno, Nevada Announces Completing Its Patent Goals and Has Received the Final Patents from Canada and Western Europe That Were Pending
Monday September 27, 5:00 am ET
RENO, Nev.--(BUSINESS WIRE)--Sept. 27, 2004--ArTec, Inc., (Pink Sheets: ATKJ - News) A Pharmaceutical Company announces completing its patent goals and receiving the final patents from Canada and Western Europe. On August 13, 2003, the Western European Patent consisting of United Kingdom, France, Spain, Germany and Italy was issued. On May 11, 2004, the patent from Canada was issued. The goals accomplished consist of five final Patents that ArTec, Inc. will utilize:
1. Canada patent issued May 11, 2004, registration number
2,293,821.
2. Western Europe patent issued August 13, 2003, registration
number 0,991,773.
3. United States patent issued August 14, 2001, registration
number 6,274,356.
4. South Korea patent issued October 29, 1998, registration number
173362.
5. Japan patent issued June 12, 1998, registration number
2,790,447.
Dr. Tai Ho Chung, M.D. Ph.D., Principal Partner and Scientific Advisor for ArTec, Inc. denotes "that having acquired, all five patents now allows ArTec, Inc. to focus on US FDA submission." Furthermore, he is encouraged by the fact that research is complete (Finished Product) and there have been no adverse side effects in human and mice studies using Tubercin on CANCER. Upon raising funds, ArTec, Inc. will move quickly into US FDA submission.
What is Tubercin?
The United States Patent issued August 14, 2001, states in the abstract summary the following:
"A carbohydrate complex, which is a mixture of low molecular-weight polysaccharides of an arabinomannan structure extracted from Mycobacterium tuberculosis, is highly effective in treating various cancer patients without incurring any adverse side effects." For further information, the US Patent and Trademark Offices's Official web site can be retrieved from ArTec, Inc.'s web site at www.artec-inc.net.
Forward-looking statements in this press release, the company cautions the investors, involve risks and uncertainties pursuant to the "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995. In addition, the company cautions investors that it undertakes no obligations or responsibilities to publicly update these forward-looking statements to reflect Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events.
ArTec, Inc. A Pharmaceutical Company whose goal is to improve the quality of life!
--------------------------------------------------------------------------------
Contact:
ArTec, Inc.
Gerry Knight, 800-388-8875
gknight@artec-inc.net
www.artec-inc.net
--------------------------------------------------------------------------------
Source: ArTec, Inc.
From what I see HTDS holds the patents (marketing rights).
Operating out of Delray Beach, Florida, Hard to Treat Diseases
Incorporated ("HTTD") holds the international marketing rights, except South
Korea, to Tubercin(R), a patented immunostimulant developed for combating
Cancer under medical patent (US Patent 6,274,356). The unique properties
unlike other cancer products are clearly stated in the abstract summary of
the patent... "A carbohydrate complex, which is a mixture of low
molecular-weight polysaccharides of an arabinomannan structure extracted
from Mycobacterium tuberculosis, is highly effective in treating various
cancer patients without incurring any adverse side effects."
ArTec Inc.,
Excutive Summary
"Tubercin"
WHAT IS TUBERCIN?
The United States Patent issued on August 14, 2001, states in the abstract the following: "A carbohydrate complex, which is a mixture of low molecular-weight poly saccharides of an arabinomannan structure extrated from Mycobacterium tuberculosis, is highly effective in treating various cancer patients without incurring any adverse side effects." For further informattion, the US Patent and Trademark Office's Official website is http://patft.uspto.gov/netacgi/tubercin.
Presently, Tubercin has been issued patents, not pending, in the following countries,
The Korean patent was issued on October 29, 1998 (Registration No. 173362).
The Japanese patent was issued on June 12, 1998 (Registration No. 2790447).
The United States patent was issued on August 14, 2001 (Registration No. 6,274,356).
The European patent was issued on August 13, 2003 (Registration No. 0991773).
The Canada patent was issued on May 11, 2004 (Registration No. 2,293,821)
A post From RB about patents.
By: salvarai
21 Sep 2004, 06:04 PM EDT
Msg. 2638 of 2640
Jump to msg. #
Well, we all knew there was a legal case pending. This is no surprise, but I just think that Dr Shinn and Mr Knight are going, once again, to try to pull a trick of the shareholders of that shell company. I will certainly post on their board to warn them....
By: salvarai
21 Sep 2004, 06:11 PM EDT
Msg. 2639 of 2640
Jump to msg. #
Looking at the news release, I notice that this is a brand new shell company with no other marketing or business expertise than the same guys (Shinn and co)who couldn't do anything under HTDS, or two previous OTCBB sheels, but just wanted to sell shares (authorizing 560 Millions of them), and keeping investors completely shut from the study progress and results.
Funny thing: they are now targeting horses!! They are far away from any real attempt at FDA aproval, HTDS will be there way before ArtC. To me, this obviously is a tactic at claiming that they stll have the patents rights. They will be so disappointed...
Is Shinn trying to pull something here?
LITIGATION WITH SHINN—BACKGROUND:
HTTD is currently involved in litigation with its former CEO Ronald Shinn and former Secretary Gerry Knight, due to their transactions of questionable legality that were contrary to the interests of HTTD’s shareholders.
On May 2, 2003 International Foam Solutions, Inc.(“IFS”) completed a share exchange agreement with Shinn, and Oklahoma companies Hard to Treat Diseases, Inc.(“HTTD”) and T-19, Inc.(“T-19”). Shinn was to receive stock in IFS in return for 100 % of the stock in HTTD and T-19.
Pursuant to the share exchange agreement, Harvey Katz resigns as President and CEO and Shinn becomes President and CEO.
As a condition of the share exchange agreement, the name of the publicly traded entity owning all three companies was changed from International Foam Solutions, Inc. to Hard to Treat Diseases, Incorporated.
Pursuant to the share exchange agreement, on May 9, 2003 Shinn and his wife are issued 350 million restricted common stock shares of HTTD.
On June 30, 2003 Shinn issues himself an additional 175 million restricted common stock shares of HTTD.
On August 18, 2003 Shinn issues himself an additional 5 million restricted common stock shares of HTTD.
During his tenure as CEO of HTTD, Shinn stated to me and others that he was very interested in selling HTTD in order to convert his equity stake to cash.
We were unaware that the Tubercin® toxicity testing was completed on October 8, 2003 and that the results were favorable, but we later discovered that Shinn was aware of the results on October 8, 2003. On October 13, 2003, Shinn, his wife, and Knight resigned.
On October 15, 2003 Shinn, acting through his lawyer, sent a letter to HTTD through one of HTTD’s shareholders stating his intention to rescind and terminate the Share Exchange Agreement dated May 2, 2003. He also tendered the original stock certificates for the 530 million restricted shares of common stock. In essence, Shinn wanted to unravel the “merger” of a publicly traded company.
Hence, we are involved in litigation with Shinn. I’m confident the outcome will be favorable for HTTD or I would not be sitting where I am working for the shareholders.
SHINN’S 530 MILLION SHARES:
The original stock certificates for Shinn’s 530 million shares are in escrow, frozen and non-voting. The shares have not been cancelled yet, they are part of HTTD’s issued and outstanding stock! The certificates are not cancelled because they are part and parcel of the terms of the share exchange agreement, which is binding and provided the company with 100% share ownership in HTTD and T-19.
Is this news good or bad for HTDS sharholders??
NEWS
September 20, 2004 07:00 AM US Eastern Timezone
ArTec, Inc., of Reno, Nevada announces Korean Partners and its Mission
BIOWIRE2K
RENO, Nev.--(BUSINESS WIRE)--Sept. 20, 2004--ArTec, Inc., (Pink Sheets:ATKJ) announces its Korean partners includes the eminent Dr. Tai Ho Chung M.D. Ph.D., inventor of Tubercin, Mr. CC Chung (son of Dr. Tai Ho Chung) and Dr. David Chai, Ph.D. The considerable experience in medical research and pharmaceutical manufacturing will greatly enhance ArTec, Inc., accomplishing its mission. Dr. Ronald Shinn, Ph.D. is the other partner that was selected as the Chairman, President and CEO. Dr. Ronald Shinn, Ph.D. a graduate of University of California at Berkely and an American citizen by birthright has been a strong advocate for the use of Tubercin to combat Cancer in the last four years. THE MISSION of ArTec is to seek US FDA and South Korea FDA approvals as soon as funds are available. ArTec, Inc., is sublicensed by Shinn Capital Group, Inc., to manufacture and distribute Tubercin in the United States and Canada. Tubercin is a finished product with a history of over 17 years of clinical experience in South Korea with no adverse side effects.
What is Tubercin? Tubercin is "carbohydrate complex, which is a mixture of low molecular-weight polysaccharides of an arabinomannan structure extract from Mycobacterium tuberculosis, is highly effective in treating various cancer patients without incurring any adverse side effects". This was cited in the August 14, 2001 (Patent Number 6274356) US Patent Documents for public information. For further information, the US Patent and Trademark Office's Official web site is retrievable at our web site: www.artec-inc.net.
Presently, Dr. Tai Ho Chung and his staff are working on a nasal spray for Tubercin. This will be an addition to the injectile administration of Tubercin. The advantages to the nasal spray are conveniences and speed of effectiveness. ArTec is pleased with the progress of the nasal spray and has samples ready for display.
At this time there have been genuine proposals to make both the nasal sprays and injectiles available for humans and animals (especially pertaining to the equine family of horses). Many Grey horses contract Melanoma Cancer and Tubercin would be a desirable product for them. In addition, Arthritis affects many horses and Tubercin could be used as a pain reliever. This does not mean that other animals do not contract cancer and suffer Arthritis. Tubercin would like to explore the animal field of medicinal products.
It would be premature to mention other products that involve Tubercin, such as, ointments of various kinds. We will keep you posted on our progress.
Forward-looking statements in this press release, the company cautions the investors, involve risks and uncertainties pursuant to the "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995. In addition, the company cautions investors that it undertakes no obligations or responsibilities to publicly update these forward-looking statements to reflect Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events.
Private investor sues market maker
NanoSignal Stockholder Sues Major Wall Street Institutions for ``Counterfeiting'' Shares
Tuesday August 31, 9:01 am ET
LAS VEGAS--(BUSINESS WIRE)--Aug. 31, 2004--A lawsuit filed in Las Vegas County Court today by a major stockholder in NanoSignal Corporation (OTC:NNOS - News) alleges that a group of major Wall Street institutions has systematically damaged the market for the stock of NNOS and many other companies by flooding the market with fraudulently manufactured, virtually counterfeit shares.
By mis-using its "Stock Borrow Program" for the personal profit of its members, rather than the purposes for which it was originally established in 1981, New York's Depository Trust Company (DTC) has created artificial shares in NNOS and other publicly-traded companies, the lawsuit (Case No. A491236) filed by Las Vegas resident Gary W. Walters claims.
One defendant in the lawsuit, Jersey City-based stockbroker Knight Trading Group, Inc. is presently "short" 447 million shares of NNOS, Mr. Walters' lawsuit alleges. That's more than double the number of NNOS legitimately issued and outstanding shares. This is only possible because DTC and its National Securities Clearing Corporation subsidiary (NSCC) have created hundreds of millions of "counterfeit" electronic shares that don't actually exist, Walters says.
The market value of NanoSignal's shares has been reduced by these illegal practices, Mr. Walters' lawsuit states, and he seeks to recover his damages from the defendants in this suit. "I believe that investors in many other companies have been hurt by the conduct of these defendants," Mr. Walters states. "I hope that my lawsuit will remind them once again that in all of their activities, the financial institutions that comprise Wall Street must always put the interests of the small investor first. If my suit prevails, Wall Street will have to undergo a major paradigm shift."
1.2 mil shares at the pop
A friend at RB:
By: newportboyri
14 Aug 2004, 09:45 AM EDT
Msg. 6403 of 6402
Jump to msg. #
Nice Week
I talked to Mario this morning and he informed me that he is glad the storm did not hit the plant. We are very busy and dont have time to play with a storm,I also asked him if anymore news was comming out soon. He said what do you think and ( laughed ) To me this was a great sign to just sit tight and be happy that I own stock in SMNC as my feelings are we are in for a nice ride at PPS well over the 1.00 mark in the next 3 months!
Have a nice weekend longs and hold your stock for the real PPS as the ante is rising fast with this one for sure :)
Bill
As capitol comes in and Smnc gets more orders, more employees and more machines, you will see this run, a very good run, why, AGAIN NOBODY ELSE HAS A PRODUCT LIKE THIS. What happened in China with this company was one of the very best moves a CEO could make. imo
Barchart gives SMNC overall now 100% buy.Short term,medium term,and long term all 100% buy.WOW.
http://quotes.barchart.com/texpert.asp?sym=smnc
Composite Indicator
Trend Spotter TM Buy
Short Term Indicators
7 Day Average Directional Indicator Buy
10 - 8 Day Moving Average Hilo Channel Buy
20 Day Moving Average vs Price Buy
20 - 50 Day MACD Oscillator Buy
20 Day Bollinger Bands Buy
Short Term Indicators Average: 100% - Buy
20-Day Average Volume - 2984761
Medium Term Indicators
40 Day Commodity Channel Index Buy
50 Day Moving Average vs Price Buy
20 - 100 Day MACD Oscillator Buy
50 Day Parabolic Time/Price Buy
Medium Term Indicators Average: 100% - Buy
50-Day Average Volume - 1642988
Long Term Indicators
60 Day Commodity Channel Index Buy
100 Day Moving Average vs Price Buy
50 - 100 Day MACD Oscillator Buy
Long Term Indicators Average: 100% - Buy
100-Day Average Volume - 1299547
Overall Average: 100% - Buy
Price Support Pivot Point Resistance
0.0350 0.0290 0.0360 0.0430
resistance would be at .04, and it is, next resistence should be .10, then look out,heavier volume and boom 1.00-1.20 yes I am long. no one else has a product like this, if you think they do, then SHOW ME. imo
#25 on Quote Leaders Pink Sheets
SMNC out before the bell, here we go.
SMNC.03.Now Barchart has 100% buy short term,and 100%Medium term.WOW.
Short Term Indicators Average: 100% - Buy
Medium Term Indicators Average: 100% - Buy
http://quotes.barchart.com/texpert.asp?sym=smnc
Composite Indicator
Trend Spotter TM Buy
Short Term Indicators
7 Day Average Directional Indicator Buy
10 - 8 Day Moving Average Hilo Channel Buy
20 Day Moving Average vs Price Buy
20 - 50 Day MACD Oscillator Buy
20 Day Bollinger Bands Buy
Short Term Indicators Average: 100% - Buy
20-Day Average Volume - 2884688
Medium Term Indicators
40 Day Commodity Channel Index Buy
50 Day Moving Average vs Price Buy
20 - 100 Day MACD Oscillator Buy
50 Day Parabolic Time/Price Buy
Medium Term Indicators Average: 100% - Buy
50-Day Average Volume - 1615701
Long Term Indicators
60 Day Commodity Channel Index Buy
100 Day Moving Average vs Price Buy
50 - 100 Day MACD Oscillator Sell
Long Term Indicators Average: 33% - Buy
100-Day Average Volume - 1279998
Overall Average: 88% - Buy
Price Support Pivot Point Resistance
0.0330 0.0150 0.0300 0.0450